PerpEquities

Samsung Biologics Co., Ltd. (SSBIOLOGICS) financials

KSC · Healthcare · Biotechnology · 5,455 employees · CEO John Chongbo Rim

Price
$1,001 -0.1%
Market cap
$48.5B
Enterprise value
₩65.5T Data as of 2026-11-21
Last report
Q3 '26 filed 2026-09-30
Next report
2027-01-27 EPS est. ₩11,137.25
Revenue (TTM)₩4.38T-20.5% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)43.4%+6.7 pp vs a year agoOperating income ₩1.9T
Net income (TTM)₩1.8T+12.9% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)₩1.45T+95.3% vs a year agoCapex ₩769B
Diluted EPS (TTM)₩38,871.96+12.8% vs a year agoSum of the last 4 quarters
Net cash₩1.28T+81.6% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
$48.5B
Updated 46m ago
Revenue
₩4.38T
Trailing 12 months
Revenue growth
–
Next fiscal year
Profit margin
41.1%
Net income / revenue, TTM
P/E
34.9×
P/S
14.9×
Price / sales, TTM
EV / EBITDA
25.9×
TTM
Free cash flow
₩1.45T
Trailing 12 months
Net income
₩1.8T
Trailing 12 months
Revenue estimate
–
Next fiscal year
Earnings
2027-01-27
Revenue est. $1.12B · Updated 46m ago
Dividend
–
No dividend

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Last report (2026-10-21): revenue beat by 9.7%, EPS missed by 13.8%Revenue ₩1.49T vs ₩1.36T expected (+9.7%); EPS ₩8,448.73 vs ₩9,799.29 (-13.8%).
  • Revenue growth slowing: -10.2% year on yearQ3 '26 revenue ₩1.49T, against an average of -9.1% over the four quarters before.
  • Operating margin 43.4% (TTM), +6.7 pp on a year agoOperating income grew -5.9% while revenue grew -20.5%.
  • 13.7% of pre-tax profit is non-operatingPre-tax income ₩2.2T vs operating income ₩1.9T (TTM). Gains on equity stakes and other one-off items lift net income and EPS - operating income is the cleaner measure of the business.
  • Capex 17.6% of revenue (a year ago 26.7%)₩769B invested in the last 4 quarters (-47.7% on a year earlier). Free cash flow ₩1.45T = 80.7% of net income.
  • Returned ₩92B to shareholders = 6.3% of free cash flowBuybacks ₩92B (a year earlier ₩0), dividends ₩0, stock-based pay ₩0 (TTM).
  • Diluted share count up 0.7% in a year46.6M diluted shares in Q3 '26, 46.3M a year earlier.
  • Net cash ₩1.28TCash + short-term investments ₩2.32T, debt incl. leases ₩1.04T; a year ago net cash ₩708B.

Last quarter: Q3 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q3 '26Year agoChange
Revenue₩1.49T₩1.66T-10.2%
Gross margin100.0%61.1%+38.9 pp
Operating income₩640B₩729B-12.2%
Operating margin43.0%43.9%-0.9 pp
Net income₩391B₩574B-31.9%
Diluted EPS₩8,391.77₩12,409.00-32.4%
Operating cash flow₩409B₩619B-34.0%
Capex₩56.9B₩114B-50.0%
Free cash flow₩352B₩505B-30.4%
R&D₩0₩107B-100.0%
Stock-based compensation₩0₩0–

Reported vs consensus

2026-10-21
ActualConsensusvs consensus
Revenue₩1.49T₩1.36T+9.7%
EPS (as estimated)₩8,448.73₩9,799.29-13.8%

From the report of 2026-10-21 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement
Operating cash flow
₩2.22T
Capex
-₩769B
Buybacks
-₩92B
Dividends
₩0
Acquisitions
-₩534B
Net debt issued
-₩157B
Stock-based compensation
₩0
Free cash flow
₩1.45T
Returned to shareholders / FCF
6.3%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)34.9×79.4×43.9× – 153.4×
EV / EBITDA25.9×44.5×28.5× – 83.5×
EV / Sales15.0×22.3×15.6× – 39.3×
Price / FCF44.8×559.2× 4 of 5 years91.6× – 1,805.4×
Price / Book7.3×8.2×5.7× – 12.1×
FCF yield2.2%0.5%-0.1% – 1.1%
Return on invested capital13.8%8.5%5.4% – 17.8%
Return on equity22.2%11.9%7.9% – 23.9%

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-21 · Amounts in KRW as reported; price and market cap in USD.